Last Updated : September 20, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Imbruvica | ibrutinib | Waldenström’s Macroglobulinemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Imcivree | setmelanotide | Bardet-Biedl syndrome | Reimburse with clinical criteria and/or conditions | Complete | ||
Imfinzi | durvalumab | Extensive-stage small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Imfinzi | durvalumab | Biliary tract cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Imfinzi | Durvalumab | Unresectable Non-Small Cell Lung Cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Imfinzi | durvalumab | resectable non-small cell lung cancer (NSCLC) | Active | |||
Imfinzi | durvalumab, carboplatin, paclitaxel | Endometrial cancer that is mismatch repair deficient (dMMR) | Pending | |||
Imfinzi and Imjudo | durvalumab and tremelimumab | unresectable hepatocellular carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Imfinzi, Imjudo | durvalumab, tremelimumab | Metastatic non-small cell lung cancer (NSCLC) | Pending | |||
Imfinzi, Lynparza | durvalumab, olaparib, carboplatin, paclitaxel | Endometrial cancer that is mismatch repair proficient (pMMR). | Pending | |||
Imvexxy | estradiol | Dyspareunia | Reimburse with clinical criteria and/or conditions | Complete | ||
Incivek | Telaprevir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | ||
Incivek | Telaprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
Incivek | Telaprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
Increlex | mecasermin | Severe primary insulin-like growth factor-1 deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
Incruse Ellipta | Umeclidinium | Chronic obstructive pulmonary disease | List with criteria/condition | Complete | ||
Inflectra | Infliximab | Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis | List with criteria/condition | Complete | ||
Inflectra (Subsequent Entry Biologic) | Infliximab | Crohn’s disease and Ulcerative Colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Inlyta | Axitinib | Metastatic Renal Cell Carcinoma | Reimburse | Complete | ||
Inlyta (RFA) | Axitinib | Metastatic Renal Cell Carcinoma | N/A | Complete | ||
Inqovi | Decitabine-Cedazuridine | Myelodysplastic Syndromes (MDS) | Reimburse with clinical criteria and/or conditions | Complete | ||
Inrebic | fedratinib | Myelofibrosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Inspiolto Respimat | Tiotropium / olodaterol | Chronic obstructive pulmonary disease | List with criteria/condition | Complete | ||
Inspra | Eplerenone | Post myocardial infarction | Do not list | Complete | ||
Inspra | Eplerenone | Heart failure, NYHA class II | Do not list at the submitted price | Complete |